- Home
- ALVR vs PSNL Comparison
ALVR vs PSNL Comparison
Compare ALVR & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVR
- PSNL
- Stock Information
- Founded
- ALVR 2013
- PSNL 2011
- Country
- ALVR United States
- PSNL United States
- Employees
- ALVR N/A
- PSNL N/A
- Industry
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- PSNL Medical Specialities
- Sector
- ALVR Health Care
- PSNL Health Care
- Exchange
- ALVR Nasdaq
- PSNL Nasdaq
- Market Cap
- ALVR 87.7M
- PSNL 321.1M
- IPO Year
- ALVR 2020
- PSNL 2019
- Fundamental
- Price
- ALVR $0.94
- PSNL $5.19
- Analyst Decision
- ALVR Sell
- PSNL Strong Buy
- Analyst Count
- ALVR 5
- PSNL 4
- Target Price
- ALVR $1.00
- PSNL $6.81
- AVG Volume (30 Days)
- ALVR 155.6K
- PSNL 439.4K
- Earning Date
- ALVR 11-04-2024
- PSNL 11-06-2024
- Dividend Yield
- ALVR N/A
- PSNL N/A
- EPS Growth
- ALVR N/A
- PSNL N/A
- EPS
- ALVR N/A
- PSNL N/A
- Revenue
- ALVR N/A
- PSNL $80,027,000.00
- Revenue This Year
- ALVR N/A
- PSNL $10.85
- Revenue Next Year
- ALVR N/A
- PSNL $8.77
- P/E Ratio
- ALVR N/A
- PSNL N/A
- Revenue Growth
- ALVR N/A
- PSNL 19.20
- 52 Week Low
- ALVR $0.58
- PSNL $0.89
- 52 Week High
- ALVR $2.49
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- ALVR 69.10
- PSNL 56.29
- Support Level
- ALVR $0.74
- PSNL $4.54
- Resistance Level
- ALVR $0.91
- PSNL $5.35
- Average True Range (ATR)
- ALVR 0.06
- PSNL 0.30
- MACD
- ALVR 0.01
- PSNL 0.05
- Stochastic Oscillator
- ALVR 94.50
- PSNL 84.71
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.